CD4 and neoplasm: The tumor cells are no longer shielded from host immune system, and consequently, the proinflammatory Th1 cytokines, such as IFNγ, may recruit adaptive CD4+ and CD8+ lymphocytes to the tumor site (figure 2B and 3B) to instigate an anti-glioma immunity (figure 4A).